Acetanilides
Labopharm Reports Results for Second Quarter 2010
Published in Gene Therapy Weekly, August 26th, 2010
"The year to date is highlighted with a number of significant milestones, culminating with the U.S. launch of OLEPTRO™ earlier this week," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "With OLEPTRO™, we now have two commercial products in the market generating revenue for the Company, both based on our CONTRAMID® technology. As we move forward, we continue to focus on the development and commercialization of differentiated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-08-26)
More Articles from Gene Therapy Weekly
- Gene Therapy
Data from University of California, Department of Neurosurgery provide new insights into gene therapy - Gene Therapy
Findings from INSERM in gene therapy reported - Phosphotransferases (Alcohol Group Acceptor)
Data on phosphotransferases (Alcohol group acceptor) detailed by researchers at University of Navarra - Gene Therapy
Deathstalker scorpion venom could improve gene therapy for brain cancer - Eurofins Mwg Operon
Eurofins MWG Operon signs contract to supply oligonucleotides to Research Councils - Gene Therapy
Findings from University of Washington, Department of Medicine broaden understanding of gene therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
